Figure 7. ApoC-III ASO treatment does not alter in vivo LPL activity or VLDL production.

(A and B) Plasma TGs were measured before and after heparin injection in WT, Ldlr^–/– Ndst1^fl/fl Alb-Cre⁺, and Ldlr^–/– Lrp1^fl/fl Alb-Cre⁺ mice treated for 4 weeks with control or ApoC-III ASO (A) after an overnight fast or (B) 3 hours after a fat challenge. Heparin was injected i.v. (50 U/mouse), and blood was sampled via tail-vein bleeding 10 minutes after injection (n = 3–5/group). (C) Hepatic VLDL production was determined in overnight-fasted Ldlr^–/– Lrp1^fl/fl Alb-Cre⁺ mice after injection with tyloxapol to inhibit lipolysis. Blood samples were collected at the indicated time points and processed to measure plasma TG accumulation and VLDL production rates (n = 3/group). Values represent the mean ± SEM. ANOVA with Bonferroni’s post-hoc test.